Idenix Pharmaceuticals (IDIX)

[DewDiligence]

IDIX Insider Shareholdings

[Updated for resignation of JP Sommadossi and award of
300K options to Ron Renaud, the former CFO who is now CEO.
Options listed below include vested and non-vested holdings.]

 
                             Shares     Options  
 Officers 
 Ron Renaud† (CEO)            15,000     855,000 
 Doug Mayers (CMO)            30,000     300,000 
 David Standring (EVP/Bio)    67,575     150,000 
 Maria Stahl‡ (Gen Counsel)        0     150,000 
 Paul Fanning (SVP/HR)         1,333     235,000 
  
 Directors 
 Charles Cramb                 7,200     160,000 
 Wayne Hockmeyer              41,708     120,000 
 Thomas Hodgson               92,324     120,000 
 Tamar Howson                      0      38,333 
 Denise Pollard-Knight             0     100,000 
 Robert Pelzer*                    0           0 
 Anthony Rosenberg*                0           0 
 ========================  =========   ========= 
 All 12 insiders             255,140   2,528,333

*Directors appointed by NVS; they do not directly own IDIX
shares or options, but NVS itself is a major shareholder.

†Named CEO and director 10/28/10.

‡Hired 10/13/10.